Calibrated Methods for Quantitative PET/CT Imaging Phase II

定量 PET/CT 成像第二阶段的校准方法

• 批准号: 8979242
• 负责人: Andinet Asmamaw Enquobahrie
• 金额: $ 74.04万
• 依托单位: KITWARE, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8979242
• 关键词: Accounting; Algorithms; Automobile Driving; Biological Markers; Calibration; Characteristics; Clinical Trials; Comparative Study; Computer software; Data; Detection; Development; Geometry; Goals; Human; Image; Image Analysis; Imaging Device; Institutes; Letters; Location; Marketing; Measurement; Measures; Methods; Modeling; Molecular; Multi-Institutional Clinical Trial; Online Systems; PET/CT scan; Patients; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Positioning Attribute; Positron-Emission Tomography; Process; Property; Protocols documentation; Radioactive; Research Contracts; Resolution; Scanning; Services; Signal Transduction; Site; Slice; Small Business Technology Transfer Research; Source; Technology; Testing; Therapeutic Agents; Thick; Time; Translating; Universities; Variant; Washington; Work; X-Ray Computed Tomography; attenuation; base; cancer therapy; clinical practice; commercialization; cost; design; imaging modality; improved; oncology; public health relevance; reconstruction; response; tool

 DESCRIPTION (provided by applicant): The overall goal of this Phase II STTR proposal is to develop a PET/CT imaging tool that will help accelerate the development of effective cancer therapies by improving the utility of oncology trials using PET imaging. The growing cost, time, and complexity of clinical trials are driving patient and pharmaceutical company demand for more objective, efficient, and accurate methods to assess the efficacy of therapeutic agents. PET/CT imaging has the potential to provide a quantitative and early assessment of drug response at a molecular level However, PET/CT use as a biomarker and response endpoint in clinical trials is limited. Key factors impeding the incorporation of PET into clinical trials are:the considerable variability in imaging methods across centers, the inconsistency in quantitative measures arising from different sites, and the variable and non-optimal methods for image analysis. In our Phase I work, we developed calibrated quantitative analysis tools that directly support improved quantitative accuracy in clinical trials using PET/CT imaging. We combined the CT 'pocket phantom', developed by Kitware, with a PET scanner calibration process developed at the University of Washington (UW) that is based on National Institute of Standards and Technology (NIST) traceable calibration sources. We also extended our automated algorithms to detect and measure the phantom, and calculate key PET image characteristics. The Phase I proof-of concept study achieved its specific aims, and in this Phase II submission, we will develop and implement the studies and tools needed to translate our proof-of-concept results to use with human imaging for clinical trials. The end goal of the phase II project is to complete all necessary work to market PET/CT calibration and measurement phantoms and analysis services.

 描述（由适用提供）：该II阶段STTR提案的总体目标是开发一种PET/CT成像工具，该工具将通过使用PET成像来改善肿瘤学试验的实用性来帮助加速有效的癌症疗法。临床试验的成本，时间和复杂性的增长是推动患者和制药公司的需求，以评估治疗剂的有效性的更客观，高效和准确的方法。 PET/CT成像有可能在分子水平上对药物反应进行定量和早期评估，但是，PET/CT用作生物标志物，并且在临床试验中的响应终点是有限的。阻碍PET纳入临床试验的关键因素是：跨中心成像方法中的相当大变量，来自不同站点引起的定量度量的不一致以及图像分析的变量和非最佳方法。在我们的I阶段工作中，我们开发了校准的定量分析工具，这些工具可以直接支持使用PET/CT成像的临床试验中提高定量准确性。我们合并了由Kitware开发的CT“ Pocket Phantom”，以及在华盛顿大学（UW）开发的PET扫描仪校准过程，该过程基于国家标准技术研究所（NIST）可跟踪的校准来源。我们还扩展了自动化算法以检测和测量幻影，并计算关键的PET图像特征。第一阶段的概念验证研究达到了其特定目标，在这二阶段提交中，我们将开发和实施转换概念验证结果所需的研究和工具，以与人类成像一起用于临床试验。第二阶段项目的最终目标是完成所有必要的工作，以销售PET/CT校准和测量幻影和分析服务。